In this study, by integrating network pharmacology approaches with rigorous experimental validation, we have, for the first time, elucidated the mechanism by which EI effectively reverses PTX resistance in BC, specifically through targeted inhibition of the Androgen Receptor (AR)/RUNX1 signaling axis. Here, RUNX1 is linked to breast cancer.